Over the past 12 months, $ARVN has been discussed by 2 distinct FinTwit voices with a combined 16 mentions, beginning on June 19, 2025. Jacob Plieth (@jacobplieth) led the conversation with 11 mentions, while Adam Feuerstein (@adamfeuerstein) contributed 5 mentions. The biotech sector dominated discussion of Arvinas Inc.

Recent activity in May 2026 centered on FDA approval of vepdegrestrant, the company's treatment developed with Pfizer. On May 1, 2026, Feuerstein reported that the FDA granted approval ahead of the June 5 PDUFA date, and that $ARVN and Pfizer were working to identify a third-party commercialization partner. By May 12, 2026, Feuerstein noted that Rigel Pharmaceuticals announced it would handle commercialization of Veppanu under modest financial terms.